Safety and Efficacy of Sofosbuvir plus Ledipasvir with and without Ribavirin for Chronic HCV Genotype-1 Infection: A Systematic Review and Meta-Analysis

Abstract

Background

Ledipasvir and sofosbuvir are new direct-acting antiviral agents for patients with HCV infection. Ledipasvir inhibits the HCV non-structural 5A protein, while sofosbuvir is a nucleotide polymerase inhibitor. Many studies have evaluated the safety and efficacy of ledipasvir and sofosbuvir combination with and without ribavirin for patients with chronic HCV genotype-1.

Methods

A computer literature search of PubMed, SCOPUS, Web of Knowledge and Cochrane CENTRAL has been conducted. Studies were screened for eligibility and data were extracted. Sustained virological response (SVR) rate and commonly reported adverse events were pooled as risk ratio (RR) using Review Manager version 5.3 for windows and OpenMeta (Analyst) software.

Results

Eight randomized controlled trials (n=1,892) were pooled in the final analysis. A 12-week ledipasvir and sofosbuvir regimen achieved SVR in 97.5% and 89% of non-cirrhotic and cirrhotic patients, respectively. A 24-week ledipasvir and sofosbuvir regimen achieved SVR in 99.6% and 92.6% in non-cirrhotic and cirrhotic patients, respectively. When ribavirin was added to the treatment regiment, the SVR did not differ significantly in either of the treatment regimens (12-week SVR: 93.9% versus 96.7%, RR=0.97, P=0.19 and 24-week SVR: 94.8% versus 97.2%, RR=0.98, P=0.24).

Conclusions

The combination of sofosbuvir and ledipasvir achieved high SVR rates (>90%) in both cirrhotic and non-cirrhotic patients with HCV genotype-1. The addition of ribavirin to this regimen did not signifcantly increase the SVR rates.

References

Mohd Hanafiah

, Groeger

, Flaxman

A.D.

, Wiersma

S.T.

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.

Hepatology 2013; 57: 1333–1342.

Lee

M-H

, Yang

H-I

, Yuan

Epidemiology and natural history of hepatitis C virus infection.

World J Gastroenterol 2014; 20: 9270–9280.

Jacobson

I.M.

, McHutchison

J.G.

, Dusheiko

Telaprevir for previously untreated chronic hepatitis C virus infection.

N Engl J Med 2011; 364: 2405–2416.

Poordad

, McCone

Jr. , Bacon

B.R.

Boceprevir for untreated chronic HCV genotype 1 infection.

N Engl J Med 2011; 364: 1195–1206.

Hézode

, Fontaine

, Dorival

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Gastroenterology 2014; 147: 132–142.e4.

Lawitz

E.J.

, Gruener

, Hill

J.M.

A Phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

J Hepatol 2012; 57: 24–31.

FDA (2014). FDA approves first combination pill to treat hepatitis C. October 10, 2014.

Afdhal

, Reddy

K.R.

, Nelson

D.R.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

N Engl J Med 2014; 370: 1483–1493.

Afdhal

, Zeuzem

, Kwo

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

N Engl J Med 2014; 370: 1889–1898.

10.

Manns

, Samuel

, Gane

E.J.

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, Phase 2 trial.

Lancet Infect Dis 2016; 16: 685–697.

11.

Kowdley

K.V.

, Gordon

S.C.

, Reddy

K.R.

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

N Engl J Med 2014; 370: 1879–1888.

12.

Bourlière

, Bronowicki

J-P

, De Ledinghen

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, Phase 2 trial (SIRIUS).

Lancet Infect Dis 2015; 15: 397–404.

13.

Charlton

, Everson

G.T.

, Flamm

S.L.

Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.

Gastroenterology 2015; 149: 649–659.

14.

Lawitz

, Poordad

F.F.

, Pang

P.S.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, Phase 2 trial.

Lancet 2014; 383: 515–523.

15.

Moher

, Liberati

, Tetzlaff

, Altman

D.G.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

PLoS Med 2009; 6: e1000097.

16.

Freeman

, Tukey

Transformations related to the angular and the square root.

Ann Math Stat 1950; 21: 607–611.

17.

Egger

, Davey Smith

, Schneider

, Minder

Bias in meta-analysis detected by a simple, graphical test.

BMJ 1997; 315: 629–634.

18.

Terrin

, Schmid

C.H.

, Lau

, Olkin

Adjusting for publication bias in the presence of heterogeneity.

Stat Med 2003; 22: 2113–2126.

19.

Gane

E.J.

, Stedman

C.A.

, Hyland

R.H.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Gastroenterology 2014; 146: 736–743. e1.

20.

Manns

M.P.

, von Hahn

Novel therapies for hepatitis C – one pill fits all?

Nat Rev Drug Discov 2013; 12: 595–610.

21.

Cheng

, Peng

, Corsa

Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885.

J Hepatol 2012; 56: S464.

22.

Dvory-Sobol

, Svarovskaia

E.S.

, Gontcharova

Resistance analyses using deep and population sequencing after 3 day monotherapy with GS-9669, a novel non-nucleoside NS5B inhibitor in genotype 1 HCV patients.

J Hepatol 2013; 58: S485.

23.

Kohli

, Sims

, Marti

Combination oral, ribavirin free, antiviral therapy to optimize treatment outcomes for hepatitis C GT-1 treatment naive patients: interim results from the NIAID SYNERGY Trial.

Hepatology 2013; 1382A–1382A.

24.

McHutchison

J.G.

, Gordon

S.C.

, Schiff

E.R.

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

N Engl J Med 1998; 339: 1485–1492.

25.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

N Engl J Med 2002; 347: 975–982.

26.

Sulkowski

, Reindollar

, Thomas

D.L.

Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a Phase II open-label study.

BioDrugs 2002; 16: 105–109.

27.

Camps

, García

, Riezu-Boj

J.I.

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon.

J Hepatol 1993; 19: 408–412.

28.

Dusheiko

, Main

, Thomas

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

J Hepatol 1996; 25: 591–598.

29.

Di Bisceglie

A.M.

, Conjeevaram

H.S.

, Fried

M.W.

Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial.

Ann Intern Med 1995; 123: 897–903.

30.

Poordad

, Lawitz

, Reddy

K.R.

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection—a randomized trial.

Gastroenterology 2013; 145: 1035–1044.e5.

31.

Sarrazin

, Dvory-Sobol

, Svarovskaia

E.S.

P0773: The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir+/-RBV.

J Hepatol 2015; 62: S620.

32.

Feld

J.J.

, Jacobson

I.M.

, Sulkowski

M.S.

Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.

Liver Int 2016; doi: 10.1111/liv.13212.

33.

European Association for Study of Liver.

EASL recommendations on treatment of hepatitis C 2015.

J Hepatol 2015; 63: 199–236.

34.

Ghany

M.G.

, Strader

D.B.

, Thomas

D.L.

, Seeff

L.B.

AASLD practice guidelines diagnosis, management, and treatment of hepatitis C: an update.

Hepatology 2015; 1335–1374.

35.

AASLD and Infectious Diseases Society of America (2015). Recommendations for testing, managing, and treating hepatitis C. (Accessed 23 May 2016). Available from http://www.hcvguidelines.org.